1 DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis[J]. J Am Acad Dermatol, 2020, 82(2): 267-281. PMID: 31279808. DOI: 10.1016/j.jaad.2019.06.1309.
2 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7): 344-347. PMID: 1090839. DOI: 10.1056/NEJM197502132920706.
3 Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis[J]. J Intern Med, 2016, 280(1): 8-23. PMID: 26602539. DOI: 10.1111/joim.12451.
4 Lundberg IE, Tj?rnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups[J]. Arthritis Rheumatol, 2017, 69(12): 2271-2282. PMID: 29106061. PMCID: PMC5846474. DOI: 10.1002/art.40320.
5 Sag E, Kale G, Haliloglu G, et al. Inflammatory milieu of muscle biopsies in juvenile dermatomyositis[J]. Rheumatol Int, 2021, 41(1): 77-85. PMID: 33106894. DOI: 10.1007/s00296-020-04735-w.
6 Thompson C, Piguet V, Choy E. The pathogenesis of dermatomyositis[J]. Br J Dermatol, 2018, 179(6): 1256-1262. PMID: 28542733. DOI: 10.1111/bjd.15607.
7 Lahouti AH, Christopher-Stine L. Polymyositis and dermatomyositis: novel insights into the pathogenesis and potential therapeutic targets[J]. Discov Med, 2015, 19(107): 463-470. PMID: 26175404.
8 Moneta GM, Pires Marafon D, Marasco E, et al. Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features[J]. Arthritis Rheumatol, 2019, 71(6): 1011-1021. PMID: 30552836. DOI: 10.1002/art.40800.
9 Cassius C, Amode R, Delord M, et al. MDA5+ dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN-κ transcript[J]. J Invest Dermatol, 2020, 140(6): 1276-1279.e7. PMID: 31955963. DOI: 10.1016/j.jid.2019.10.020.
10 Zhao LJ, Wang Q, Zhou B, et al. The role of immune cells in the pathogenesis of idiopathic inflammatory myopathies[J]. Aging Dis, 2021, 12(1): 247-260. PMID: 33532139. PMCID: PMC7801271. DOI: 10.14336/AD.2020.0410.
11 Crotty S. T follicular helper cell differentiation, function, and roles in disease[J]. Immunity, 2014, 41(4): 529-542. PMID: 25367570. PMCID: PMC4223692. DOI: 10.1016/j.immuni.2014.10.004.
12 Wilkinson MGL, Radziszewska A, Wincup C, et al. Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies[J]. Rheumatology (Oxford), 2020, 59(1): 194-204. PMID: 31292651. DOI: 10.1093/rheumatology/kez252.
13 Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis[J]. Arthritis Rheum, 1985, 28(7): 796-803. PMID: 2409985. DOI: 10.1002/art.1780280711.
14 王涛, 石景丽, 张亚妹, 等. 抗Mi-2抗体不同亚型的临床异质性研究[J]. 中日友好医院学报, 2017, 31(1): 7-10. DOI: 10.3969/j.issn.1001-0025.2017.01.002.
15 Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies[J]. Medicine (Baltimore), 2013, 92(4): 223-243. PMID: 23877355. PMCID: PMC3721421. DOI: 10.1097/MD.0b013e31829d08f9.
16 Nguyen M, Do V, Yell PC, et al. Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups[J]. Acta Neuropathol Commun, 2020, 8(1): 125. PMID: 32758284. PMCID: PMC7405369. DOI: 10.1186/s40478-020-01007-3.
17 Sag E, Demir S, Bilginer Y, et al. Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis[J]. Semin Arthritis Rheum, 2021, 51(1): 95-100. PMID: 33360233. DOI: 10.1016/j.semarthrit.2020.10.007.
18 Reed AM, Crowson CS, Hein M, et al. Biologic predictors of clinical improvement in rituximab-treated refractory myositis[J]. BMC Musculoskelet Disord, 2015, 16: 257. PMID: 26382217. PMCID: PMC4574570. DOI: 10.1186/s12891-015-0710-3.
19 Kim Y, Song KS, Sohn EH, et al. Anti-TIF1γ antibody and the expression of TIF1γ in idiopathic inflammatory myopathies[J]. Int J Rheum Dis, 2019, 22(2): 314-320. PMID: 30398003. DOI: 10.1111/1756-185X.13424.
20 Fiorentino DF, Kuo KR, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis[J]. J Am Acad Dermatol, 2015, 72(3): 449-455. PMID: 25595720. PMCID: PMC4351728. DOI: 10.1016/j.jaad.2014.12.009.
21 Yamasaki Y, Kobayashi N, Akioka S, et al. Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicenter study[J]. Rheumatology (Oxford), 2021. PMID: 33576399. DOI: 10.1093/rheumatology/keab108. Epub ahead of print.
22 Fujimoto M, Watanabe R, Ishitsuka Y, et al. Recent advances in dermatomyositis-specific autoantibodies[J]. Curr Opin Rheumatol, 2016, 28(6): 636-644. PMID: 27533321. DOI: 10.1097/BOR.0000000000000329.
23 Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, et al. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis[J]. Rheumatology (Oxford), 2018, 57(2): 388-396. PMID: 29149307. PMCID: PMC5850766. DOI: 10.1093/rheumatology/kex413.
24 Ikeda N, Yamaguchi Y, Kanaoka M, et al. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis[J]. J Dermatol, 2020, 47(5): 490-496. PMID: 32103537. DOI: 10.1111/1346-8138.15284.
25 Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features[J]. J Am Acad Dermatol, 2018, 78(4): 776-785. PMID: 29229575. DOI: 10.1016/j.jaad.2017.12.010.
26 张瑾, 程江, 闵月, 等. 抗MDA5抗体阳性幼年皮肌炎合并严重闭塞性血管坏死1例并文献复习[J]. 医学综述, 2020, 26(15): 3117-3120. DOI: 10.3969/j.issn.1006-2084.2020.15.038.
27 李冬梅, 汪利, 刘明月, 等. 幼年皮肌炎临床特征与肌炎抗体相关性分析[J]. 中华儿科杂志, 2020, 58(12): 966-972. PMID: 33256317. DOI: 10.3760/cma.j.cn112140-20200724-00751.
28 Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies[J]. Curr Rheumatol Rep, 2018, 20(5): 28. PMID: 29637414. DOI: 10.1007/s11926-018-0733-5.
29 侯俊, 闫淯淳, 吴凤岐, 等. 幼年皮肌炎和多发性肌炎合并肺间质病变临床、影像学特点[J]. 中国医刊, 2021, 56(4): 428-431. DOI: 10.3969/j.issn.1008-1070.2021.04.021.
30 Li LB, Wang Q, Wen XT, et al. Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease[J]. Oncotarget, 2017, 8(44): 76129-76140. PMID: 29100298. PMCID: PMC5652692. DOI: 10.18632/oncotarget.19050.
31 Ryan ME, Cortez D, Dietz KR, et al. Anti-MDA5 juvenile idiopathic inflammatory myopathy with second-degree heart block but no skin or lung involvement: a case report[J]. BMC Rheumatol, 2021, 5(1): 8. PMID: 33795018. PMCID: PMC8017641. DOI: 10.1186/s41927-021-00180-9.
32 Sabbagh S, Almeida de Jesus A, Hwang S, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib[J]. Brain, 2019, 142(11): e59. PMID: 31603187. PMCID: PMC6821280. DOI: 10.1093/brain/awz293.
33 Suzuki S, Uruha A, Suzuki N, et al. Integrated diagnosis project for inflammatory myopathies: an association between autoantibodies and muscle pathology[J]. Autoimmun Rev, 2017, 16(7): 693-700. PMID: 28479486. DOI: 10.1016/j.autrev.2017.05.003.
34 Aouizerate J, De Antonio M, Bader-Meunier B, et al. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis[J]. Rheumatology (Oxford), 2018, 57(5): 873-879. PMID: 29474663. DOI: 10.1093/rheumatology/kex516.
35 Oddis CV, Fertig N, Goel A. Clinical and serological characterization of the anti-MJ antibody in childhood myositis[J]. Arthritis Rheumatol, 1997, 40: S139.
36 许瑛杰, 周志轩, 侯俊, 等. 严重胃肠道受累的幼年皮肌炎4例病例系列报告[J]. 中国循证儿科杂志, 2019, 14(5): 355-358. DOI: 10.3969/j.issn.1673-5501.2019.05.007.
37 Albayda J, Pinal-Fernandez I, Huang W, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients[J]. Arthritis Care Res (Hoboken), 2017, 69(11): 1771-1776. PMID: 28085235. PMCID: PMC5509530. DOI: 10.1002/acr.23188.
38 Patwardhan A. The value of intravenous immunoglobulin therapy in idiopathic inflammatory myositis in the current transformed era of biologics[J]. Cureus, 2020, 12(2): e7049. PMID: 32128294. PMCID: PMC7034746. DOI: 10.7759/cureus.7049.
39 Wu Q, Wedderburn LR, McCann LJ. Juvenile dermatomyositis: latest advances[J]. Best Pract Res Clin Rheumatol, 2017, 31(4): 535-557. PMID: 29773272. DOI: 10.1016/j.berh.2017.12.003.
40 Lee S, Findeisen J, McLean C, et al. Recalcitrant ulcers associated with anti-small ubiquitin-like modifier activating enzyme-positive dermatomyositis treated with surgery followed by intravenous immunoglobulin[J]. Australas J Dermatol, 2018, 59(1): e76-e78. PMID: 28660625. DOI: 10.1111/ajd.12659.
41 Ge YP, Lu X, Shu XM, et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts[J]. Sci Rep, 2017, 7(1): 188. PMID: 28298642. PMCID: PMC5428032. DOI: 10.1038/s41598-017-00240-6.
42 Kishi T, Tani Y, Okiyama N, et al. Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease: a case report[J]. Pediatr Rheumatol Online J, 2021, 19(1): 34. PMID: 33740993. PMCID: PMC7980636. DOI: 10.1186/s12969-021-00532-2.
43 Wolstencroft PW, Casciola-Rosen L, Fiorentino DF. Association between autoantibody phenotype and cutaneous adverse reactions to hydroxychloroquine in dermatomyositis[J]. JAMA Dermatol, 2018, 154(10): 1199-1203. PMID: 30140893. PMCID: PMC6233745. DOI: 10.1001/jamadermatol.2018.2549.